Is Amarin Corporation PLC (AMRN) overvalued? · rev $228.6M
Amarin Corporation PLC (AMRN) is a drug manufacturers - general company listed on US.
This page asks whether Amarin Corporation PLC (AMRN) looks expensive on cached numbers — not a short thesis.
Latest reported AMRN revenue for 2024-12-31 was $228.6M. Net income was -$82.2M. Revenue was down 25.5% from 2023-12-31 to 2024-12-31. AMRN currently screens at market cap $292.1M.
AMRN currently screens at market cap $292.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AMRN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AMRN stock page for the full model, not this heading.
Not investment advice.